Getting a Next-Generation Genome Editing Therapy for Sickle Cell Disease Back on Track

Matthew Porteus, co-founder and CEO of Kamau Therapeutics, discusses the company’s genome editing technology, what’s now understood about the serious adverse event that occurred in a Graphite Bio clinical trial of the company’s lead experimental therapy, and the development path forward for the therapy.